1
|
Patel D, Knauer JP, Cao D, Betti R, Nora R, Shvydky A, Gopalaswamy V, Lees A, Sampat S, Donaldson WR, Regan SP, Stoeckl C, Forrest CJ, Glebov VY, Harding DR, Bonino MJ, Janezic RT, Wasilewski D, Fella C, Shuldberg C, Murray J, Guzman D, Serrato B. Effects of Laser Bandwidth in Direct-Drive High-Performance DT-Layered Implosions on the OMEGA Laser. Phys Rev Lett 2023; 131:105101. [PMID: 37739360 DOI: 10.1103/physrevlett.131.105101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 07/05/2023] [Accepted: 08/16/2023] [Indexed: 09/24/2023]
Abstract
In direct-drive inertial confinement fusion, the laser bandwidth reduces the laser imprinting seed of hydrodynamic instabilities. The impact of varying bandwidth on the performance of direct-drive DT-layered implosions was studied in targets with different hydrodynamic stability properties. The stability was controlled by changing the shell adiabat from (α_{F}≃5) (more stable) to (α_{F}≃3.5) (less stable). These experiments show that the performance of lower adiabat implosions improves considerably as the bandwidth is raised indicating that further bandwidth increases, beyond the current capabilities of OMEGA, would be greatly beneficial. These results suggest that the future generation of ultra-broadband lasers could enable achieving high convergence and possibly high gains in direct drive ICF.
Collapse
Affiliation(s)
- D Patel
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, New York 14623, USA
| | - J P Knauer
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - D Cao
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - R Betti
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, New York 14623, USA
- Department of Physics and Astronomy, University of Rochester, New York 14623, USA
| | - R Nora
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Shvydky
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - V Gopalaswamy
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - A Lees
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - S Sampat
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - W R Donaldson
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - S P Regan
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - C Stoeckl
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - C J Forrest
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - V Yu Glebov
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - D R Harding
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - M J Bonino
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - R T Janezic
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - D Wasilewski
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - C Fella
- Laboratory for Laser Energetics, University of Rochester, New York 14623, USA
| | - C Shuldberg
- General Atomics, San Diego, California 92186, USA
| | - J Murray
- General Atomics, San Diego, California 92186, USA
| | - D Guzman
- General Atomics, San Diego, California 92186, USA
| | - B Serrato
- General Atomics, San Diego, California 92186, USA
| |
Collapse
|
2
|
Nagy AV, Leschziner G, Eriksson SH, Lees A, Noyce AJ, Schrag A. Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease. Parkinsonism Relat Disord 2023; 109:105312. [PMID: 36827949 DOI: 10.1016/j.parkreldis.2023.105312] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 01/14/2023] [Accepted: 01/30/2023] [Indexed: 02/05/2023]
Abstract
BACKGROUND Mild cognitive impairment (MCI) is commonly present at the time of Parkinson's Disease (PD) diagnosis, but its prevalence amongst individuals at increased risk of PD is unclear. METHODS Cognition was assessed using the Montreal Cognitive Assessment (MoCA) in 208 participants in the PREDICT-PD study, and 25 participants with REM-sleep behaviour disorder (RBD). Prevalence of MCI level I was determined in all participants, and level II MCI in the RBD sub-group. RESULTS Total MoCA scores were worse in the higher risk than the lower risk group defined as those below the 15th percentile of risk (p = 0.009), and in the RBD group compared to all healthy participants (p < 0.001). The prevalence of MCI level I was 12.8% in the lower-risk, 21.9% in the higher-risk (within the highest 15th percentile) and 64% in RBD participants; 66% of RBD participants had MCI level II with multi-domain MCI, but particularly attention and memory deficits. CONCLUSIONS Cognitive impairment is increased in different groups at higher risk of PD, particularly in the subgroup formally diagnosed with RBD.
Collapse
Affiliation(s)
- A V Nagy
- Department of Clinical and Behavioural Neurosciences, University College London Queen Square Institute of Neurology, United Kingdom
| | - G Leschziner
- Sleep Disorders Centre and Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, Dept of Basic and Clinical Neuroscience, Institute of Psychology, Psychiatry and Neuroscience, King's College London, United Kingdom
| | - S H Eriksson
- National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, United Kingdom
| | - A Lees
- Rita Lila Weston Institute of Neurological Studies, University College London Queen Square Institute of Neurology, United Kingdom
| | - A J Noyce
- Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom
| | - A Schrag
- Department of Clinical and Behavioural Neurosciences, University College London Queen Square Institute of Neurology, United Kingdom.
| |
Collapse
|
3
|
Cao SH, Patel D, Lees A, Stoeckl C, Rosenberg MJ, Gopalaswamy V, Wen H, Huang H, Shvydky A, Betti R, Ren C. Predicting hot electron generation in inertial confinement fusion with particle-in-cell simulations. Phys Rev E 2022; 106:055214. [PMID: 36559357 DOI: 10.1103/physreve.106.055214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 11/14/2022] [Indexed: 11/30/2022]
Abstract
A series of two-dimensional particle-in-cell simulations with speckled laser drivers was carried out to study hot electron generation in direct-drive inertial confinement fusion on OMEGA. Scaling laws were obtained for hot electron fraction and temperature as functions of laser/plasma conditions in the quarter-critical region. Using these scalings and conditions from hydro simulations, the temporal history of hot electron generation can be predicted. The scalings can be further improved to predict hard x-rays for a collection of OMEGA warm target implosions within experimental error bars. These scalings can be readily implemented into inertial confinement fusion design codes.
Collapse
Affiliation(s)
- S H Cao
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA.,Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - D Patel
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA.,Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - A Lees
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA
| | - C Stoeckl
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - M J Rosenberg
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - V Gopalaswamy
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA.,Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - H Wen
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - H Huang
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - A Shvydky
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA
| | - R Betti
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA.,Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA.,Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - C Ren
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14627, USA.,Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14627, USA.,Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| |
Collapse
|
4
|
Shah RC, Cao D, Aghaian L, Bachmann B, Betti R, Campbell EM, Epstein R, Forrest CJ, Forsman A, Glebov VY, Goncharov VN, Gopalaswamy V, Harding DR, Hu SX, Igumenshchev IV, Janezic RT, Keaty L, Knauer JP, Kobs D, Lees A, Mannion OM, Mohamed ZL, Patel D, Rosenberg MJ, Shmayda WT, Stoeckl C, Theobald W, Thomas CA, Volegov P, Woo KM, Regan SP. Bound on hot-spot mix in high-velocity, high-adiabat direct-drive cryogenic implosions based on comparison of absolute x-ray and neutron yields. Phys Rev E 2022; 106:L013201. [PMID: 35974626 DOI: 10.1103/physreve.106.l013201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Accepted: 06/29/2022] [Indexed: 06/15/2023]
Abstract
In laser-driven implosions for laboratory fusion, the comparison of hot-spot x-ray yield to neutron production can serve to infer hot-spot mix. For high-performance direct-drive implosions, this ratio depends sensitively on the degree of equilibration between the ion and electron fluids. A scaling for x-ray yield as a function of neutron yield and characteristic ion and electron hot-spot temperatures is developed on the basis of simulations with varying degrees of equilibration. We apply this model to hot-spot x-ray measurements of direct-drive cryogenic implosions typical of the direct-drive designs with best ignition metrics. The comparison of the measured x-ray and neutron yields indicates that hot-spot mix, if present, is below a sensitivity estimated as ∼2% by-atom mix of ablator plastic into the hot spot.
Collapse
Affiliation(s)
- R C Shah
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D Cao
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - L Aghaian
- General Atomics, San Diego, California 92121, USA
| | - B Bachmann
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - R Betti
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - E M Campbell
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - R Epstein
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C J Forrest
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - A Forsman
- General Atomics, San Diego, California 92121, USA
| | - V Yu Glebov
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - V N Goncharov
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - V Gopalaswamy
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D R Harding
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - S X Hu
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - I V Igumenshchev
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - R T Janezic
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - L Keaty
- General Atomics, San Diego, California 92121, USA
| | - J P Knauer
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D Kobs
- General Atomics, San Diego, California 92121, USA
| | - A Lees
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - O M Mannion
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - Z L Mohamed
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D Patel
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - M J Rosenberg
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - W T Shmayda
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C Stoeckl
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - W Theobald
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C A Thomas
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - P Volegov
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - K M Woo
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - S P Regan
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| |
Collapse
|
5
|
Lees A, Betti R, Knauer JP, Gopalaswamy V, Patel D, Woo KM, Anderson KS, Campbell EM, Cao D, Carroll-Nellenback J, Epstein R, Forrest C, Goncharov VN, Harding DR, Hu SX, Igumenshchev IV, Janezic RT, Mannion OM, Radha PB, Regan SP, Shvydky A, Shah RC, Shmayda WT, Stoeckl C, Theobald W, Thomas C. Experimentally Inferred Fusion Yield Dependencies of OMEGA Inertial Confinement Fusion Implosions. Phys Rev Lett 2021; 127:105001. [PMID: 34533333 DOI: 10.1103/physrevlett.127.105001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 07/21/2021] [Indexed: 06/13/2023]
Abstract
Statistical modeling of experimental and simulation databases has enabled the development of an accurate predictive capability for deuterium-tritium layered cryogenic implosions at the OMEGA laser [V. Gopalaswamy et al.,Nature 565, 581 (2019)10.1038/s41586-019-0877-0]. In this letter, a physics-based statistical mapping framework is described and used to uncover the dependencies of the fusion yield. This model is used to identify and quantify the degradation mechanisms of the fusion yield in direct-drive implosions on OMEGA. The yield is found to be reduced by the ratio of laser beam to target radius, the asymmetry in inferred ion temperatures from the ℓ=1 mode, the time span over which tritium fuel has decayed, and parameters related to the implosion hydrodynamic stability. When adjusted for tritium decay and ℓ=1 mode, the highest yield in OMEGA cryogenic implosions is predicted to exceed 2×10^{14} fusion reactions.
Collapse
Affiliation(s)
- A Lees
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14623, USA
| | - R Betti
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14623, USA
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14623, USA
| | - J P Knauer
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - V Gopalaswamy
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14623, USA
| | - D Patel
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
- Department of Mechanical Engineering, University of Rochester, Rochester, New York 14623, USA
| | - K M Woo
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - K S Anderson
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - E M Campbell
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D Cao
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - J Carroll-Nellenback
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - R Epstein
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C Forrest
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - V N Goncharov
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - D R Harding
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - S X Hu
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - I V Igumenshchev
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - R T Janezic
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - O M Mannion
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14623, USA
| | - P B Radha
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - S P Regan
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - A Shvydky
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - R C Shah
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - W T Shmayda
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C Stoeckl
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - W Theobald
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - C Thomas
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| |
Collapse
|
6
|
Lees A, Reichmann H, Rocha J, Magalhães D, Soares-da-Silva P. Onset of drug-related adverse events in Parkinson's disease patients treated with opicapone in clinical practice: OPTIPARK post-hoc analysis. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Foltynie T, Tolosa E, Ferreira J, Antonini A, Lees A, Ebersbach G, Rascol O, Rocha JF, Magalhães D, Soares-da-Silva P. Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Ferreira J, Lees A, Ebersbach G, Santos A, Magalhães D, Rocha JF, Soares-da-Silva P. Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Rascol O, Poewe W, Ferreira J, Lees A, Santos AT, Magalhães D, Rocha J, Soares-da-Silva P. Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Reichmann H, Lees A, Rocha J, Magalhães D, Soares-da-Silva P. Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations: findings from the OPTIPARK study. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Rocha F, Poewe W, Rascol O, Lees A, Ferreira J, Santos A, Magalhaes D, Soares-da-Silva P. Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Ferreira J, Lees A, Poewe W, Rascol O, Santos A, Magalhaes D, Rocha F, Soares-da-Silva P. Switching entacapone ‘non-responders’ to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Rocha F, Stocchi F, Lees A, Ferreira J, Poewe W, Rascol O, Santos A, Magalhaes D, Soares-da-Silva P. Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Costa R, Ferreira J, Lees A, Tolosa E, Poewe W, Ikedo F, Magalhaes D, Rocha F, Soares-da-Silva P. Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Rocha F, Ferreira J, Lees A, Tolosa E, Stocchi F, Santos A, Magalhaes D, Soares-da-Silva P, Savic N. Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Hauser R, Rascol O, Poewe W, Ferreira J, Lees A, Klepitskaya O, Liang G, Santos A, Magalhaes D, Rocha F, Soares-da-Silva P. Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Lees A, Ferreira J, Antonini A, Reichmann H, Costa R, Magalhaes D, Rocha F, Soares-da-Silva P. Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Santos A, Lees A, Ferreira J, Rascol O, Antonini A, Gama H, Magalhaes D, Rocha F, Soares-da-Silva P. Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Costa R, Lees A, Ferreira J, Rascol O, Stocchi F, Ikedo F, Magalhaes D, Rocha F, Soares-da-Silva P. Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Lees A, Ferreira J, Rascol O, Poewe W, Tolosa E, Gama H, Magalhaes D, Rocha F, Soares-da-Silva P. Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Lees A, Ferreira J, Rascol O, Poewe W, Stocchi F, Santos A, Magalhaes D, Rocha F, Soares-da-Silva P. Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Costa R, Ferreira J, Lees A, Tolosa E, Poewe W, Ikedo F, Diogo M, Rocha F, Soares-da-Silva P. Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Ferreira J, Lees A, Rascol O, Poewe W, Ikedo F, Magalhaes D, Rocha F, Soares-da-Silva P. Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 2019; 26:953-960. [PMID: 30681754 PMCID: PMC6593852 DOI: 10.1111/ene.13914] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 01/21/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE The aim was to evaluate the efficacy of the catechol-O-methyltransferase inhibitor opicapone (25 and 50 mg) as adjunct therapy to levodopa in a pooled population of Parkinson's disease patients who participated in the pivotal double-blind trials of opicapone and their 1-year open-label extensions. METHODS Data (placebo, opicapone 25 mg and opicapone 50 mg) from the BIPARK-1 and BIPARK-2 double-blind and open-label studies were combined. The studies had similar designs, eligibility criteria and assessment methods. The primary efficacy variable in both double-blind studies was the change from baseline in absolute OFF time based on patient diaries. RESULTS Double-blind treatment with opicapone (25 and 50 mg) significantly reduced absolute daily OFF time from a baseline of 6.1-6.6 h. The mean (and 95% confidence interval) treatment effect versus placebo was -35.1 (-62.1, -8.2) min (P = 0.0106) for the 25 mg dose and -58.1 (-84.5, -31.7) min (P < 0.0001) for the 50 mg dose. Reductions in OFF time were mirrored by significant increases in ON time without troublesome dyskinesia (P < 0.05 and P < 0.0001 for the 25 and 50 mg doses, respectively). No significant differences were observed for ON time with troublesome dyskinesia. Patient diary results from the open-label phase indicated a maintenance of effect for patients previously treated with opicapone 50 mg. The group previously treated with the 25 mg dose benefitted with further optimization of therapy during the open-label phase, whilst switching from placebo to opicapone led to significant reductions in OFF time and increased ON time. CONCLUSIONS Over at least 1 year of open-label therapy, opicapone consistently reduced OFF time and increased ON time without increasing the frequency of troublesome dyskinesia.
Collapse
Affiliation(s)
- J J Ferreira
- Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Torres Vedras, Portugal.,CNS - Campus Neurológico Sénior, Torres Vedras, Portugal
| | - A Lees
- Reta Lila Weston Institute, University College London, London, UK
| | - J-F Rocha
- Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal
| | - W Poewe
- Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
| | - O Rascol
- Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN Network, University Hospital of Toulouse, INSERM, University Toulouse 3, Toulouse, France
| | - P Soares-da-Silva
- Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.,Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal.,Center for Drug Discovery and Innovative Medicines, MedInUP, University Porto, Porto, Portugal
| |
Collapse
|
25
|
Lees A, Ferreira J, Costa R, Santos A, Rocha J, Soares-Da-Silva P. 127EFFICACY AND SAFETY OF OPICAPONE IN PATIENTS OVER 70 YEARS WITH PARKINSON’S DISEASE AND MOTOR FLUCTUATIONS. Age Ageing 2019. [DOI: 10.1093/ageing/afy205.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Lees
- National Hospital for Neurology and Neurosurgery, London, UK
| | - J Ferreira
- Neurologica Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
| | - R Costa
- Dept. Research and Development, BIAL, Portugal
| | - A Santos
- Dept. Research and Development, BIAL, Portugal
| | - J Rocha
- Dept. Research and Development, BIAL, Portugal
| | - P Soares-Da-Silva
- Dept. Research and Development, BIAL, Portugal
- Dept. Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Portugal
| |
Collapse
|
26
|
Lees A, Ferreira J, Poewe W, Rascol O, Santos A, Ikedo F, Oliveira I, Rocha J, Soares-da-Silva P. Off- and on-time responder post-HOC analyses of pooled opicapone phase III studies. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Ferreira J, Lees A, Rascol O, Poewe W, Santos A, Ikedo F, Oliveira I, Rocha J, Soares-da-Silva P. Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension study. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Abstract
The vertical reaction force was measured during impact landings following a vertical jump. It was observed that variations between subjects occurred in the magnitude of the peak force over the first 150-200 ms after impact. This period of the landing is termed the impact absorption phase. Two extreme cases of impact landings are taken for analysis. These are referred to as ‘hard’ and ‘soft’ landings, describing the magnitude of the vertical force peak during impact absorption. These differences are produced as a result of the interactions which occur between the individual segments of the human body. The segmental contribution to the total force curve was derived by film analysis techniques. The specific influence of each segment on the total force curve was isolated and made comparable with other segments by using the relative acceleration of the segment mass centre to the lower joint about which it rotates. By using this variable to compare hard and soft landings, it was established that a soft landing was produced by a phased and controlled deceleration of body segments.
Collapse
Affiliation(s)
- A Lees
- Department of Sport and Recreation Studies, Liverpool Polytechnic
| |
Collapse
|
29
|
Durnin L, Moreland N, Lees A, Mutafova-Yambolieva VN. A commonly used ecto-ATPase inhibitor, ARL-67156, blocks degradation of ADP more than the degradation of ATP in murine colon. Neurogastroenterol Motil 2016; 28:1370-81. [PMID: 27060478 PMCID: PMC5002237 DOI: 10.1111/nmo.12836] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 03/14/2016] [Indexed: 01/24/2023]
Abstract
BACKGROUND Adenosine 5'-triphosphate (ATP) is released extracellularly as a neurotransmitter and an autocrine or paracrine mediator in numerous systems, including the gastrointestinal tract. It is rapidly degraded to active and inactive metabolites by membrane-bound enzymes. Investigators frequently use inhibitors of ATP hydrolysis such as ARL-67156 and POM-1 to suppress the catabolism of ATP and prolong its effects in pharmacological studies. Our aim was to investigate directly the effects of ARL-67156 and POM-1 on the degradation of ATP and adenosine 5'-diphosphate (ADP) in mouse colonic muscles. METHODS The degradation of ATP and ADP was evaluated by superfusing tissues with 1,N(6) -etheno-ATP (eATP) and 1,N(6) -etheno-ADP (eADP) as substrates and monitoring the decrease in substrate and increase in products (i.e., eADP, eAMP, and e-adenosine) by high-performance liquid chromatography techniques with fluorescence detection. Relaxation responses to etheno-derivatized and non-derivatized ATP and ADP were examined in isometric tension experiments. KEY RESULTS ARL-67156 inhibits the degradation of ADP but not of ATP, whereas POM-1 inhibits the degradation of ATP but not of ADP in murine colonic muscles. Consequently, ARL-67156 enhances relaxation responses to both ATP and ADP, whereas POM-1 reduces relaxation to ATP and does not affect relaxation to ADP. CONCLUSIONS & INFERENCES Studies that use ARL-67156 to inhibit ATP degradation in smooth muscle likely evaluate responses to accumulated ADP rather than ATP. POM-1 appears to be a more selective inhibitor of ATP degradation in the mouse colon. The choice of pharmacological tools in studies on extracellular ATP signaling may affect the interpretation of experimental data in functional studies.
Collapse
Affiliation(s)
- L. Durnin
- Department of Physiology and Cell Biology; University of Nevada School of Medicine; Reno NV USA
| | - N. Moreland
- Department of Physiology and Cell Biology; University of Nevada School of Medicine; Reno NV USA
| | - A. Lees
- Department of Physiology and Cell Biology; University of Nevada School of Medicine; Reno NV USA
| | | |
Collapse
|
30
|
Herrmann H, Lees A. On the influence of the rheological boundary conditions on the fibre orientations in the production of steel fibre reinforced concrete elements. Proc Estonian Acad Sci 2016. [DOI: 10.3176/proc.2016.4.08] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
31
|
Miranda M, Bustamante M, Mena F, Lees A. Manganic Parkinsonism in Chile and the introduction of levodopa. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.09.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Ling H, Ling H, de Silva R, Massey LA, Courtney R, Hondhamuni G, Bajaj N, Lowe J, Holton JL, Lees A, Revesz T. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol 2014; 40:149-63. [PMID: 23432126 PMCID: PMC4260147 DOI: 10.1111/nan.12037] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 02/15/2013] [Indexed: 12/11/2022]
Abstract
Aims Since the first description of the classical presentation of progressive supranuclear palsy (PSP) in 1963, now known as Richardson's syndrome (PSP-RS), several distinct clinical syndromes have been associated with PSP-tau pathology. Like other neurodegenerative disorders, the severity and distribution of phosphorylated tau pathology are closely associated with the clinical heterogeneity of PSP variants. PSP with corticobasal syndrome presentation (PSP-CBS) was reported to have more tau load in the mid-frontal and inferior-parietal cortices than in PSP-RS. However, it is uncertain if differences exist in the distribution of tau pathology in other brain regions or if the overall tau load is increased in the brains of PSP-CBS. Methods We sought to compare the clinical and pathological features of PSP-CBS and PSP-RS including quantitative assessment of tau load in 15 cortical, basal ganglia and cerebellar regions. Results In addition to the similar age of onset and disease duration, we demonstrated that the overall severity of tau pathology was the same between PSP-CBS and PSP-RS. We identified that there was a shift of tau burden towards the cortical regions away from the basal ganglia; supporting the notion that PSP-CBS is a ‘cortical’ PSP variant. PSP-CBS also had less severe neuronal loss in the dorsolateral and ventrolateral subregions of the substantia nigra and more severe microglial response in the corticospinal tract than in PSP-RS; however, neuronal loss in subthalamic nucleus was equally severe in both groups. Conclusions A better understanding of the factors that influence the selective pathological vulnerability in different PSP variants will provide further insights into the neurodegenerative process underlying tauopathies.
Collapse
Affiliation(s)
| | - H Ling
- Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, UK; Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK; Sara Koe PSP Research Centre, Institute of Neurology, University College London, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Tennant S, Simon R, Wang J, Pasetti M, Ernst R, Lees A, Galen J, Levine M. Bivalent vaccine strategies for invasive non-typhoidal Salmonella infections. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
34
|
Lees A, Ferreira J, Costa R, Rocha JF, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P. Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.391] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Schottlaender L, Sailer A, Polke J, Ling H, de Silva R, Holton J, Revesz T, Lees A, Houlden H. C9orf72 expansion in atypical parkinsonism. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.2316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Glass P, Lees A, Bacellar A, Zijlmans J, Katzenschlager R, Silveira-Moriyama L. Clinical Features of Vascular Parkinsonism in Pathologically Confirmed Cases (P06.074). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p06.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Cardoso F, Vale T, Lees A. Gowers' Queen Square Case Notes on Chorea (S59.004). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s59.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Moscovich M, Munhoz R, Teive H, Raskin S, Liu J, McFarland K, Ashizawa T, Lees A, Silveira-Moriyama L. To Investigate Olfactory Impairment in Cerebellar Ataxia (P05.015). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Vandrovcova J, Anaya F, Kay V, Lees A, Hardy J, de Silva R. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr Alzheimer Res 2011; 7:726-34. [PMID: 20704554 DOI: 10.2174/156720510793611619] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2010] [Accepted: 06/02/2010] [Indexed: 11/22/2022]
Abstract
Fibrillar aggregates of abnormally hyperphosphorylated tau protein are the major component of the pathological entities, including intraneuronal neurofibrillary tangles that define the broad class of late-onset neurodegenerative disorders called the tauopathies. Mutations in the tau gene (MAPT) causing familial frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) confirm that tau protein dysfunction could be a primary cause of neuronal loss. However, in the sporadic tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) where MAPT mutation is absent, common variation in MAPT that defines the H1 and H2 haplotype clades strongly influences disease risk. Surprisingly, this influence on risk extends to sporadic Parkinson's disease (PD), traditionally not defined as a tauopathy. This review will focus on recent work aimed at elucidating the mechanistic basis of this haplotype-specific effect on disease risk, implicating elevated levels of MAPT expression, particularly via increased transcription and/or alterations in splicing. This conforms to an emerging picture of a shared mechanism that underlies the fundamental process(es) leading to neuronal death. Increased availability of the fibrillogenic protein substrates of the pathological aggregates that define several neurodegenerative proteopathies, eg α-synuclein in PD, β-amyloid in AD and tau in the tauopathies, contributes to causation and risk in the familial and sporadic forms of these disorders, respectively.
Collapse
Affiliation(s)
- J Vandrovcova
- Reta Lila Weston Institute & Department of Molecular Neuroscience, UCL Institute of Neurology, 1 Wakefield Street, London, WC1N 1PJ, UK
| | | | | | | | | | | |
Collapse
|
40
|
Camargos ST, Gurgel-Giannetti J, Lees A, Hardy J, Singleton A, Cardoso F. Low prevalence of PANK2 mutations in Brazilian patients with early onset generalised dystonia and basal ganglia abnormalities on MRI. J Neurol Neurosurg Psychiatry 2011; 82:1059-60. [PMID: 20551478 PMCID: PMC4979548 DOI: 10.1136/jnnp.2009.200808] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Touba M, Lees A. Effects of heavy resistance exercise on fatigue and recovery during period of 48 h post-exercise in females. Br J Sports Med 2010. [DOI: 10.1136/bjsm.2010.078972.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Singh-Curry V, Bunzeck N, O'Sullivan S, Molloy M, Perry R, Bain P, Lees A, Duzel E, Husain M. PATH50 Novelty-seeking and risk-taking behaviour in subtypes of Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 2010. [DOI: 10.1136/jnnp.2010.226340.18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Mead S, Linehan J, Beck J, Caine D, Gandhi S, Wadsworth JDF, Joiner S, Gallujipali D, Hyare H, Lees A, Holton J, Sandberg M, Revesz T, Carswell C, Warren JD, Collinge J, Wood N. PATU2 Novel truncation mutation of PRNP causes chronic diarrhoea, sensory neuropathy and autonomic failure associated with prion protein deposition in the cerebral blood vessels and small bowel. Journal of Neurology, Neurosurgery & Psychiatry 2010. [DOI: 10.1136/jnnp.2010.226340.31] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Wu K, O'Sullian S, Politis M, Bose S, Lees A, Piccini P. PAW21 Rewarding visual cues increase dopamine neurotransmission in Parkinson's patients with impulse control disorders: a PET study. Journal of Neurology, Neurosurgery & Psychiatry 2010. [DOI: 10.1136/jnnp.2010.226340.50] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
|
46
|
|
47
|
Davendralingam N, Davagnanam I, Djamshidian A, Lees A. Progressive dysphagia, dysarthria, dystonia, and tremor. BMJ 2010; 340:c1213. [PMID: 20237396 DOI: 10.1136/bmj.c1213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Robinson MA, Barton GJ, Lees A, Sett P. Analysis of tetraplegic reaching in their 3D workspace following posterior deltoid-triceps tendon transfer. Spinal Cord 2010; 48:619-27. [DOI: 10.1038/sc.2009.193] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Morley J, Cohen A, Silveira-Moriyama L, Williams D, Katzenschlager R, Moberg P, Adelman J, Hower R, Rick J, Lees A, Hawkes C, Weintraub D, Doty R, Duda J. P2.026 Optimizing olfactory testing for the diagnosis of Parkinson's disease. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70377-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Segarane B, Li A, Paudel R, Scholz S, Neumann J, Lees A, Revesz T, Hardy J, Mathias CJ, Wood NW, Holton J, Houlden H. Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 2009; 72:1185-6. [PMID: 19332698 DOI: 10.1212/01.wnl.0000345356.40399.eb] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- B Segarane
- Department of Molecular Neuroscience and Reta Lila Weston Laboratories, Institute of Neurology, University College London, Queen Square, UK WC1N 3BG
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|